Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Legend BiotechLEGN +2.59%73 3-1 Month Momentum % is -15.90% as of Aug. 22, 2026. GuruFocus rates LEGN with a GF Score™ of 73/100 and a GF Value™ of $79.37 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, Legend Biotech ranks worse than 69.26% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-22), Legend Biotech's 3-1 Month Momentum % is -15.90%.
The industry rank for Legend Biotech's 3-1 Month Momentum % or its related term are showing as below:
LEGN's 3-1 Month Momentum % is ranked worse than 69.26% of 1386
companies
in the Biotechnology industry
Industry Median: -7.01
vs LEGN: -15.90
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Legend Biotech 3-1 Month Momentum % Related Terms
LEGN vs TNGX, ACAD, CAI: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Legend Biotech's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Legend Biotech's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (LEGN) has a 3-1 Month Momentum % of -15.90% as of Aug. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Legend Biotech and its competitors. According to the industry distribution chart, Legend Biotech ranks #960 out of 1386 companies in the Biotechnology industry, placing it in the top 69.3%.
Is Legend Biotech's 3-1 Month Momentum % too high?
Legend Biotech's current 3-1 Month Momentum % is -15.90%. Based on the distribution chart, Legend Biotech ranks #960 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's 3-1 Month Momentum % compare to TNGX and ACAD?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #960 out of 1386 companies for 3-1 Month Momentum %. This places Legend Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Legend Biotech and its competitors. Legend Biotech's current 3-1 Month Momentum % is -15.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Significantly Undervalued. The stock's GF Value™ is $79.37, compared to a current price of $21.82 — trading 72.5% below its estimated fair value. The current 3-1 Month Momentum % is -15.90%. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Legend Biotech (LEGN), the current 3-1 Month Momentum % is -15.90% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $21.82 is trading 72.5% below its estimated GF Value™ of $79.37.
GuruFocus considers Legend Biotech to be Significantly Undervalued.
Key valuation signals for LEGN:
3-1 Month Momentum %: -15.90%
GF Value™: $79.37 vs. price of $21.82 (72.5% below fair value)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score
Get the complete analysis for LEGN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
